{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T04:10:07Z","timestamp":1794975007595,"version":"4.9.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background\/Objectives<\/jats:title>\n            <jats:p>A positive patient experience is a key element of quality healthcare but data on the patient experience is rarely collected as part of routine care. This study analysed survey and discussion group comments from patients treated for neovascular AMD (nAMD) treatment to identify key elements of the patient experience.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Subjects\/Methods<\/jats:title>\n            <jats:p>Free text comments from an online Macular Society member survey and quotes from subsequent, local, in-person patient discussion groups were reviewed. Thematic analysis was used to code the responses and to identify major themes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Analysis include 167 free text comments from Macular Society members and quotes from 2 local discussion groups, with patients and their carers. Key themes, important for the patient experience, included: time and availability of appointments, accessibility and duration of clinic visits, the delivery and quality of care, communication and access to written information and confidence in the healthcare team.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Feedback from patients with nAMD and their carers identified a number of key themes that are associated with either a positive or negative patient experience. Construction of an appropriate patient-reported experience measure and collection of data, either locally or nationally, would help identify areas of the care pathway where improvements may be necessary. Improving the patient experience may encourage adherence to and persistence with treatment and the outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41433-025-03915-x","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T10:42:19Z","timestamp":1752576139000},"page":"2565-2569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A thematic analysis of patients\u2019 experiences of receiving treatment for Neovascular age-related macular degeneration (nAMD)"],"prefix":"10.1038","volume":"39","author":[{"given":"Julie","family":"Hapeshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7715-9808","authenticated-orcid":false,"given":"Samantha","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4388-243X","authenticated-orcid":false,"given":"Martin","family":"McKibbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8513-710X","authenticated-orcid":false,"given":"Peter H.","family":"Scanlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"3915_CR1","unstructured":"DHSC. Health and Social Care Act 2012. https:\/\/www.legislation.gov.uk\/ukpga\/2012\/7\/section\/2."},{"key":"3915_CR2","doi-asserted-by":"publisher","first-page":"982","DOI":"10.12968\/bjon.2014.23.18.982","volume":"23","author":"D Palmer","year":"2014","unstructured":"Palmer D, Miedany YE. PREMs in inflammatory arthritis: from guidelines to standard practice. Br J Nurs. 2014;23:982\u20135.","journal-title":"Br J Nurs"},{"key":"3915_CR3","doi-asserted-by":"publisher","first-page":"831","DOI":"10.2147\/PPA.S81975","volume":"9","author":"F Tzelepis","year":"2015","unstructured":"Tzelepis F, Sanson-Fisher RW, Zucca AC, Fradgley EA. Measuring the quality of patient-centered care: why patient-reported measures are critical to reliable assessment. Patient Prefer Adherence. 2015;9:831\u20135.","journal-title":"Patient Prefer Adherence"},{"key":"3915_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/bjaed\/mkw060","volume":"17","author":"C Kingsley","year":"2017","unstructured":"Kingsley C, Patel S. Patient-reported outcome measures and patient-reported experience measures. BJA Educ. 2017;17:137\u201344.","journal-title":"BJA Educ"},{"key":"3915_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ophtha.2007.03.008","volume":"115","author":"TY Wong","year":"2008","unstructured":"Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115:116\u201326.","journal-title":"Ophthalmology"},{"key":"3915_CR6","unstructured":"RCOphth. Age related macular degeneration services: recommendations. 2024. https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2021\/08\/CommissioningGuidance-AMD-Services-Recommendations.pdf."},{"key":"3915_CR7","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1038\/s41433-023-02474-3","volume":"37","author":"R Jones","year":"2023","unstructured":"Jones R, Stratton IM, Scanlon PH, Theodoropoulou S. Disengagement and loss to follow-up in intravitreal injection clinics for neovascular age-related macular degeneration. Eye. 2023;37:3186\u201390.","journal-title":"Eye"},{"key":"3915_CR8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.oret.2019.07.010","volume":"4","author":"RR Soares","year":"2020","unstructured":"Soares RR, Mellen P, Garrigan H, Obeid A, Wibbelsman TD, Borkar D, et al. Outcomes of eyes lost to follow-up with neovascular age-related macular degeneration receiving intravitreal anti-vascular endothelial growth factor. Ophthalmol Retin. 2020;4:134\u201340.","journal-title":"Ophthalmol Retin"},{"key":"3915_CR9","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1097\/IAE.0000000000001494","volume":"37","author":"JH Kim","year":"2017","unstructured":"Kim JH, Chang YS, Kim JW. Natural course of patients discontinuing treatment for age-related macular degeneration and factors associated with visual prognosis. Retina. 2017;37:2254\u201361.","journal-title":"Retina"},{"key":"3915_CR10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","volume":"128","author":"M Okada","year":"2021","unstructured":"Okada M, Mitchell P, Finger RP, Eldem B, Talks SJ, Hirst C, et al. Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology. 2021;128:234\u201347.","journal-title":"Ophthalmology"},{"key":"3915_CR11","unstructured":"RCOphth. First Annual Report of the Age-related macular degeneration (AMD) audit. 2023. https:\/\/www.rcophth.ac.uk\/wp-content\/uploads\/2023\/02\/NOD-AMDAudit-Full-Annual-Report-2023-2.pdf."},{"key":"3915_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1108\/JHOM-06-2021-0242","volume":"36","author":"S De Rosis","year":"2021","unstructured":"De Rosis S, Barchielli C, Vainieri M, Belle N. The relationship between healthcare service provision models and patient experience. J Health Organ Manag. 2021;36:1\u201324.","journal-title":"J Health Organ Manag"},{"key":"3915_CR13","unstructured":"MS. The Macular Society: Understanding patients\u2019 perceptions of wet AMD treatment in 2020. 2020. https:\/\/www.macularsociety.org\/media\/ucwbmhm4\/patientsperceptions-of-wet-amd-treatments-survey-report.pdf."},{"key":"3915_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Res Psychol. 2006;3:77\u2013101.","journal-title":"Qualitative Res Psychol"},{"key":"3915_CR15","unstructured":"Braun V, Clarke V. Thematic analysis: a practical guide. Sage Publications Ltd; London, UK 2021."},{"key":"3915_CR16","unstructured":"Corbin J, Strauss A. Basics of qualitative research: techniques and procedures for developing grounded theory. 4th ed: Sage Ltd; USA 2015."},{"key":"3915_CR17","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/aos.13847","volume":"96","author":"E Jelin","year":"2018","unstructured":"Jelin E, Wisloff T, Moe MC, Heiberg T. Development and testing of a patient-derived questionnaire for treatment of neovascular age-related macular degeneration: dimensions of importance in treatment of neovascular age-related macular degeneration. Acta Ophthalmol. 2018;96:804\u201311.","journal-title":"Acta Ophthalmol"},{"key":"3915_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13548506.2016.1274040","volume":"23","author":"J Boyle","year":"2018","unstructured":"Boyle J, Vukicevic M, Koklanis K, Itsiopoulos C, Rees G. Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychol Health Med. 2018;23:127\u201340.","journal-title":"Psychol Health Med"},{"key":"3915_CR19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s40123-022-00631-7","volume":"12","author":"SJ Talks","year":"2023","unstructured":"Talks SJ, Daien V, Mitchell P, Aslam T, Barratt J, Biberger A, et al. The patient voice in neovascular age-related macular degeneration: findings from a qualitative study. Ophthalmol Ther. 2023;12:561\u201375.","journal-title":"Ophthalmol Ther"},{"key":"3915_CR20","doi-asserted-by":"publisher","first-page":"e012790","DOI":"10.1136\/bmjopen-2016-012790","volume":"7","author":"EM Boxell","year":"2017","unstructured":"Boxell EM, Amoaku WM, Bradley C. Healthcare experiences of patients with agerelated macular degeneration: have things improved? Cross-sectional survey responses of Macular Society members in 2013 compared with 1999. BMJ Open. 2017;7:e012790.","journal-title":"BMJ Open"},{"key":"3915_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1477-7525-4-97","volume":"4","author":"J Mitchell","year":"2006","unstructured":"Mitchell J, Bradley C. Quality of life in age-related macular degeneration: a review of the literature. Health Qual Life Outcomes. 2006;4:97.","journal-title":"Health Qual Life Outcomes"},{"key":"3915_CR22","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1136\/bjophthalmol-2014-306544","volume":"99","author":"AK Krezel","year":"2015","unstructured":"Krezel AK, Hogg RE, Azuara-Blanco A. Patient-reported outcomes in randomised controlled trials on age-related macular degeneration. Br J Ophthalmol. 2015;99:1560\u20134.","journal-title":"Br J Ophthalmol"},{"key":"3915_CR23","doi-asserted-by":"crossref","unstructured":"Wang R, McClard CK, Laswell S, Mahmoudzadeh R, Salabati M, Ammar M, et al. Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII). BMJ Open Ophthalmol. 2022;7:e001188.","DOI":"10.1136\/bmjophth-2022-001188"},{"key":"3915_CR24","doi-asserted-by":"publisher","first-page":"e000669","DOI":"10.1136\/bmjophth-2020-000669","volume":"6","author":"CK McClard","year":"2021","unstructured":"McClard CK, Wang R, Windham V, Munoz J, Gomez S, Fried S, et al. Questionnaire to Assess Life Impact of Treatment by Intravitreal Injections (QUALITII): Development of a patient-reported measure to assess treatment burden of repeat intravitreal injections. BMJ Open Ophthalmol. 2021;6:e000669.","journal-title":"BMJ Open Ophthalmol"},{"key":"3915_CR25","unstructured":"Commission TCQ. Opening the door to change. 2018. https:\/\/www.cqc.org.uk\/sites\/default\/files\/20181224_openingthedoor_report.pdf."},{"key":"3915_CR26","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/eye.2018.1","volume":"32","author":"JM Sparrow","year":"2018","unstructured":"Sparrow JM, Grzeda MT, Frost NA, Johnston RL, Liu CSC, Edwards L, et al. CatPROM5: a brief psychometrically robust self-report questionnaire instrument for cataract surgery. Eye. 2018;32:796\u2013805.","journal-title":"Eye"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03915-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03915-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03915-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T10:41:08Z","timestamp":1757241668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03915-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":26,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3915"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03915-x","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the last year, PHS has received meeting expenses from Boehringer and speaker fees from Bayer and Topcon. MM has educational travel grants from Bayer and Roche and has had advisory board\/consultancy fees from Bayer, Roche and Apellis. The other authors do not declare any conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}